From attending key oral sessions, clinical science symposiums and poster presentations to the simple pleasures of chatting with colleagues during coffee breaks, we left the

从参加重要的口头会议、临床科学研讨会和海报展示，到在咖啡休息期间与同事聊天的简单乐趣，我们离开了

2025 American Society of Clinical Oncology meeting

2025年美国临床肿瘤学会会议

with a renewed commitment to advancing global cancer care as part of a global collaborative oncology community, and welcomed the chance to explore the latest innovative scientific advances and to share insights on how to translate that science to better meeting patient needs.

重新致力于推进全球癌症护理，作为全球肿瘤学合作社区的一部分，并欢迎有机会探索最新的创新科学进展，分享如何将这些科学成果转化以更好地满足患者需求的见解。

This is especially important as funding and health policy changes in the broader healthcare ecosystem raise questions among stakeholders regarding the potential impacts on oncology research and development.

这在更广泛的医疗生态系统中，随着资金和卫生政策的变化，利益相关者对肿瘤学研发潜在影响提出质疑的情况下尤为重要。

From the practical wisdom of emphasising

从强调的实践智慧

exercise

锻炼

to improve survival in colon cancer to the association of

为了提高结肠癌的生存率与相关性

glucagon-like peptide 1 receptor agonists

胰高血糖素样肽1受体激动剂

use with a reduction in obesity-related cancer risk, the excitement around ideas, possibilities and pathways in oncology research and development can seem limitless. In the wealth of breakthrough data findings coming out of ASCO, we noticed a pattern in discussions.

在减少与肥胖相关的癌症风险方面，肿瘤学研究与开发中的创意、可能性和途径令人兴奋不已。在ASCO发布的众多突破性数据中，我们注意到讨论中出现了一种模式。

As we collectively leverage invaluable insights to further extend survival for advanced cancers and to improve the toxicity profiles of treatments, those of us working in oncology research and development daily want to see even more real-world progress for patients earlier in their cancer journeys. Indeed, we heard from global pharmaceutical and emerging biopharma leadership on the forefront of oncology innovation who emphasised the need to shift our mindset and work to better understand the biology of cancer and improve personalised treatment regimens to get in front of this debilitating disease..

当我们共同利用宝贵的见解来进一步延长晚期癌症的生存期并改善治疗的毒性特征时，我们这些从事肿瘤学研究与开发的人每天都希望看到患者在癌症早期阶段获得更多的实际进展。确实，我们听到了全球制药巨头和新兴生物制药领域前沿的肿瘤创新领导者的声音，他们强调需要转变我们的思维模式，努力更好地理解癌症的生物学特性，并改进个性化治疗方案，以领先于这种使人衰弱的疾病。

During the meeting, we were pleased to see multiple data highlights that exemplified just how the oncology community is inching toward “getting ahead” of cancer, including the notable points of progress below.

在会议期间，我们很高兴看到多个数据亮点，展示了肿瘤学界是如何逐步“走在”癌症前面的，其中包括以下显著的进展。

The role of advanced liquid biopsies: Individualising treatment regimens

先进液体活检的作用：个性化治疗方案

There were engaging discussions onsite regarding

现场就相关问题展开了引人入胜的讨论，

SERENA-6

赛琳娜-6

, the first global, double-blind Phase III trial to use a circulating tumor DNA-guided approach to detect emerging resistance in first-line therapy ahead of advanced HR-positive breast cancer progression. Presented in a

，这是首个全球性、双盲的III期试验，采用循环肿瘤DNA指导的方法，在晚期HR阳性乳腺癌进展之前检测一线治疗中出现的耐药性。在一项

plenary session

全体会议

at ASCO and concurrently published in the

在ASCO上发表，并同时刊登在

New England Journal of Medicine

新英格兰医学杂志

, the results demonstrated that switching to treatment with camizestrant, a next-generation, oral selective oestrogen receptor degrader, if a treatment-resistant ESR1 mutation is detected during first-line treatment can help reduce risk of disease progression or death by 56%.

，结果表明，如果在一线治疗期间检测到治疗耐药的 ESR1 突变，转而使用下一代口服选择性雌激素受体降解剂卡米泽斯特治疗，可帮助降低疾病进展或死亡的风险达 56%。

Putting theory into practice, the trial findings emphasised the clinical value regular liquid biopsy testing of ctDNA can have in detecting ESR1 mutations as they emerge to determine which patients may benefit from switching treatments to delay progression and maintain their quality of life. Being able to track small traces of specific tumour DNA in the blood and spot signs of treatment resistance earlier can be a powerful tool to help guide individualised treatment regimens with speed and not allow the cancer to gain traction..

将理论付诸实践，试验结果强调了定期进行ctDNA液体活检在临床中的价值，可以检测ESR1突变的出现，从而确定哪些患者可能受益于更换治疗以延缓疾病进展并维持生活质量。能够追踪血液中微量的特定肿瘤DNA并及早发现治疗耐药迹象，是一项强大的工具，可帮助快速指导个体化治疗方案，不给癌症发展可乘之机。

Also presented at ASCO, the

同时在ASCO上发表的还有

ARTEMIS-PC study results

ARTEMIS-PC研究结果

showed that ctDNA-based monitoring held promise for predicting treatment response and prognosis in patients with unresectable pancreatic cancer, with detection rates increasing with advancing stages of disease.

基于ctDNA的监测有希望预测无法切除的胰腺癌患者的治疗反应和预后，其检出率随着疾病的进展而增加。

When aiming to find genetic variations of cancer, it will be exciting to see where research will head to further examine disease detection and related treatment adjustments for advanced breast cancer, pancreatic cancer, and other forms via these next-generation liquid biopsies. Even as we evaluate these new tools for better treatment decisions and address the shortcomings of the more traditional methods of tumour sampling, we can also recognise the benefit to our patients from avoiding the discomfort and complications of more .

当旨在寻找癌症的遗传变异时，令人兴奋的是，研究将进一步探索通过这些下一代液体活检技术对晚期乳腺癌、胰腺癌及其他类型癌症的疾病检测与相关治疗调整的方向。即使我们在评估这些新工具以改进治疗决策，并解决传统肿瘤取样方法的不足之处时，我们也能认识到避免更多不适和并发症给患者带来的益处。

invasive biopsy techniques

侵入性活检技术

.

。

Understanding who is eligible for certain treatments based on genetic variations will ensure earlier detection and better health outcomes with less invasive procedures and therapies. However, to fully recognise the promise of liquid biopsies for cancer detection, patient access to testing is critical.

基于基因变异了解哪些人适合某些治疗将确保更早的检测和更好的健康结果，同时减少侵入性手术和疗法的使用。然而，要充分实现液体活检在癌症检测中的潜力，患者能否获得检测至关重要。

Recognising this, in late May, England’s National Health Service .

认识到这一点，五月底，英格兰的国家医疗服务体系。

announced

宣布

it will offer tens of thousands of patients with lung and breast cancer the ctDNA test to “speed up access to targeted therapy.”

它将为数万名肺癌和乳腺癌患者提供ctDNA测试，以“加快获得靶向治疗的速度”。

Expanding earlier lines of cancer therapy

扩展早期的癌症治疗线路

The FDA’s

美国食品药品监督管理局的

Project FrontRunner

前沿计划

initiative aims to encourage drug companies to consider the most appropriate line of treatment setting when developing cancer therapies, such as in earlier clinical settings. Moving faster to earlier lines of therapy creates the potential to sharpen our understanding of a treatment's effects, improve comparisons to standard of care options, and reduce the time it takes to bring effective new therapies to patients.

该倡议旨在鼓励制药公司考虑最合适的治疗环境，例如在更早期的临床环境中开发癌症疗法。更快地推进到更早的治疗线，有可能加深我们对治疗效果的理解，改善与标准治疗方案的比较，并缩短将有效的新疗法带给患者的时间。

At ASCO 2025, we saw several examples of what we, as an industry, can do to ensure patients do not have to wait until they have failed several therapies to be considered for a novel treatment option/regimen..

在2025年的ASCO会议上，我们看到了一些例子，展示了我们作为行业可以采取哪些措施，确保患者不必等到多次治疗失败后才被考虑接受一种新的治疗选择/方案。

First-line combination therapy for BRAF V600E-mutant metastatic colorectal cancer

BRAF V600E突变转移性结直肠癌的一线联合治疗

Presented in a

呈现于

late-breaking abstract

最新突破性摘要

and simultaneously published in

同时发布于

NEJM

新英格兰医学杂志

, survival data from the Phase III BREAKWATER study in patients with BRAF V600E-mutant metastatic colorectal cancer showed that patients treated with encorafenib in combination with EGFR inhibitor cetuximab and chemotherapy had a 51% reduced risk of death and 47% reduced risk of disease progression than those treated with standard-of-care chemotherapy with or without bevacizumab. .

，来自III期BREAKWATER研究的生存数据显示，在BRAF V600E突变型转移性结直肠癌患者中，接受恩科拉非尼联合EGFR抑制剂西妥昔单抗和化疗的患者，其死亡风险比接受标准化疗（是否联合贝伐珠单抗）的患者降低了51%，疾病进展风险降低了47%。

It is worth noting that, though 8% to 12% of people with metastatic colorectal cancer have the BRAF V600E mutations, no BRAF inhibitor has been approved in the US for first-line treatment for this high-risk subgroup. Encorafenib, marketed by Pfizer under the name Braftovi, received a late 2024

值得注意的是，尽管8%到12%的转移性结直肠癌患者存在BRAF V600E突变，但目前美国尚未批准任何BRAF抑制剂用于这一高风险亚组的一线治疗。辉瑞公司销售的Encorafenib（商品名Braftovi）在2024年末获得了批准。

accelerated FDA approval

加速FDA批准

based on objective response rate. This updated data on progression-free and overall survival will serve as post-marketing confirmatory evidence to support full approval of this combination therapy as a first-line treatment.

基于客观缓解率。更新的无进展生存期和总生存期数据将作为上市后确证性证据，以支持该联合疗法作为一线治疗获得完全批准。

Earlier treatment for early-stage gastric cancer

早期胃癌的早期治疗

With hopes to bring innovative immunotherapies to patients in earlier disease stages and target specific biomarkers, rather than treating broadly, findings from the

希望通过在疾病早期阶段为患者带来创新的免疫疗法，并针对特定的生物标志物进行治疗，而不是广泛治疗，研究结果表明

Phase III MATTERHORN study

第三期MATTERHORN研究

were shared during a plenary session at the conference. Findings showed that patients with early-stage and locally advanced gastric and gastroesophageal junction cancers receiving perioperative treatment with durvalumab in combination with standard treatment regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival compared to chemotherapy alone.

在会议的全体会议上分享了相关结果。结果显示，与单独使用化疗相比，接受度伐利尤单抗联合氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛标准治疗方案的早期和局部晚期胃癌及胃食管交界处癌症患者，在无事件生存的主要终点上表现出具有统计学意义和临床意义的改善。

More than two-thirds of patients (67.4%) treated with this combination therapy remained event-free for two years..

超过三分之二的患者（67.4%）在接受这种联合治疗后两年内无事件发生。

Fine-tuning long-term therapy goals for multiple myeloma

调整多发性骨髓瘤的长期治疗目标

Data presented at major oncology conferences last year, including

去年在主要肿瘤学会议上展示的数据，包括

ASCO 2024

ASCO 2024

, signified increased care options for improved long-term outcomes in patients with multiple myeloma. Building on that progress, the focus at this year’s ASCO turned to the use of minimal residual disease testing as a tool in the treatment decision-making paradigm. MRD testing is used to quantify residual cancer cells with more sensitivity when cancer is no longer detectable by commonly used methods, such as bone marrow morphology, computed tomography scans, and magnetic resonance imaging..

，意味着为多发性骨髓瘤患者提供更多的治疗选择，以改善其长期预后。在此进展的基础上，今年ASCO的重点转向将微小残留病检测作为治疗决策范式中的工具。当癌症无法通过常用方法（如骨髓形态学、计算机断层扫描和磁共振成像）检测到时，MRD检测可用于更灵敏地量化残留癌细胞。

Two key reports coming out of the meeting focused on the use of MRD for MM-specific treatment decisions are noted below. Though follow-up is needed to confirm the results, these studies have the potential to shift the treatment paradigm in multiple myeloma using MRD as a major decision-making tool:

会议中产生的两份关于使用MRD进行多发性骨髓瘤特定治疗决策的关键报告如下所示。尽管仍需后续研究来确认结果，但这些研究有潜力通过将MRD作为主要决策工具，改变多发性骨髓瘤的治疗模式：

The

The

MIDAS Phase III trial

MIDAS第三阶段试验

demonstrated no benefit to a transplant-based approach compared to consolidation in patients who achieved MRD-negativity to the threshold of 10-6 by next generation sequencing after induction therapy.

对于通过诱导治疗后达到10^-6水平的MRD阴性的患者，基于移植的方法相较于巩固治疗并未显示出益处。

The

The

Phase III PERSEUS trial

三期PERSEUS试验

showed sustained MRD-negativity at two years in 55.8% of patients receiving the combination treatment regimen of the monoclonal antibody daratumumab with bortezomib, lenalidomide and dexamethasone, which correlated with a 98% progression-free survival at four years. These encouraging results prompted discussions of discontinuing treatment in patients with prolonged MRD negativity with continued monitoring of MRD status..

在使用单克隆抗体达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松的组合治疗方案的患者中，55.8%的患者在两年时显示持续的MRD阴性，这与四年时98%的无进展生存率相关。这些令人鼓舞的结果促使对长期MRD阴性的患者进行继续监测MRD状态的同时停药的讨论。

Driving scientific innovation with intention

有目的地推动科学创新

Scientific innovations mean even more when progress can be directly observed and measured in ways that genuinely impact patients’ daily lives. At ASCO 2025, seeing the breadth of how the global oncology community is coming together to drive collaborations and explore the furthest corners of cancer innovation with purpose is inspiring, especially as it pertains to advancing earlier interventions and enhancing disease detection..

科学创新的意义在于，当进步能够以真正影响患者日常生活的方式被直接观察和衡量时更为显著。在2025年ASCO大会上，看到全球肿瘤学界如何团结一致，推动合作，并有针对性地探索癌症创新的最前沿领域，令人倍感鼓舞，尤其是在推进早期干预和加强疾病检测方面。

Here’s to many more steps toward getting in front of cancer.

为迈向抗癌前沿的更多步伐干杯。

About the authors

关于作者

Michael Armstrong, MD, PhD, Senior Director, Medical, Hematology-Oncology Center of Excellence, IQVIA Biotech

迈克尔·阿姆斯特朗，医学博士，哲学博士，高级总监，血液学-肿瘤学卓越中心，IQVIA生物科技

Michael Armstrong is a paediatric haematologist-oncologist with a special interest in basic science and translational research in neuroblastoma. As a member of the Hematology-Oncology Center of Excellence, he works closely with biotech companies to assist with new drug development and the administration of clinical trials with an emphasis on immuno-oncology and paediatric indications.

迈克尔·阿姆斯特朗是一位儿科血液肿瘤学家，对神经母细胞瘤的基础科学研究和转化研究有特别的兴趣。作为血液学-肿瘤学卓越中心的成员，他与生物技术公司密切合作，协助新药开发和临床试验的管理，重点关注免疫肿瘤学和儿科适应症。

In his previous work with the world’s largest paediatric cancer research group, the Children’s Oncology Group, Armstrong participated in the neuroblastoma section, including the biology subcommittee and a trial study committee..

在之前与世界上最大的儿科癌症研究组织——儿童肿瘤学组的合作中，阿姆斯特朗参与了神经母细胞瘤部门的工作，包括生物学小组委员会和一个试验研究委员会。

Gerhard du Toit, Global Head, Oncology, IQVIA Biotech

Gerhard du Toit，IQVIA生物技术全球肿瘤学主管

Overseeing the team to optimise strategic plans and enhance delivery for early to late-phase oncology clinical trials, du Toit is committed to delivering compliant, expeditious, and ethical solutions that respect patient safety, meet Good Clinical Practice requirements and add value to oncology-focused companies.

监督团队优化战略计划，并加强从早期到晚期肿瘤临床试验的交付工作，杜托伊特致力于提供合规、迅速且符合伦理的解决方案，这些方案尊重患者安全，满足良好临床实践要求，并为专注于肿瘤学的公司增加价值。

To his role, du Toit brings more than 25 years of experience in project, clinical and data management, business development, and statistics. He also has operational management of trial programs across Europe, the US, the Middle East, Africa, and Asia..

杜托伊特在项目、临床和数据管理、业务发展以及统计方面拥有超过25年的经验，并将这些经验带入了他的角色。他还负责欧洲、美国、中东、非洲和亚洲的试验项目的运营管理。

Matt Simmons, Senior Director, Oncology Strategy, IQVIA Biotech

马特·西蒙斯，高级总监，肿瘤战略，IQVIA生物技术

In his current role, Simmons provides strategic guidance to IQVIA’s oncology operational teams and consultative oversight for biopharma and biotech sponsors developing therapeutics to treat cancer. He has more than 25 years of experience across all phases of drug development with large and small pharmaceuticals, CROs, consulting, and software companies, as well as managing a leading oncology Phase I clinical research unit in London..

在目前的职位上，Simmons 为 IQVIA 的肿瘤学运营团队提供战略指导，并为开发生物制药和生物技术治疗癌症的赞助商提供咨询监督。他在药物开发的所有阶段拥有超过 25 年的经验，曾服务于大型和小型制药公司、CRO、咨询公司及软件公司，并管理过伦敦一家领先的肿瘤学一期临床研究单位。